Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy- The SCARLET Randomized Clinical Trial
JL Vincent, B Francois, I Zabolotskikh et al for The Scarlet Study Group
JAMA, 2019, online first May 2019
This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules,
exam preparation tools, teaching aids and much more, login here, or Become a Member to register
|
May
|
Comment
Does administration of a recombinant human soluble thrombomodulin reduce mortality of critically ill patients with sepsis-associated coagulopathy?
The rationale behind asking this question;